{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T01:33:37Z","timestamp":1790645617642,"version":"4.1.0"},"reference-count":87,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.jconrel.2021.05.046","type":"journal-article","created":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T23:03:09Z","timestamp":1622588589000},"page":"398-407","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":48,"special_numbering":"C","title":["Tailoring of P-glycoprotein for effective transportation of actives across blood-brain-barrier"],"prefix":"10.1016","volume":"335","author":[{"given":"Nazneen","family":"Pathan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pravin","family":"Shende","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2021.05.046_bb0005","doi-asserted-by":"crossref","first-page":"107554","DOI":"10.1016\/j.pharmthera.2020.107554","article-title":"Dysfunction of ABC transporters at the blood-brain barrier: role in neurological disorders","volume":"213","author":"Gil-Martins","year":"2020","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.jconrel.2021.05.046_bb0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms21020591","article-title":"Structural, molecular, and functional alterations of the blood-brain barrier during epileptogenesis and epilepsy: a cause, consequence, or","volume":"21","author":"L\u00f6scher","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jconrel.2021.05.046_bb0015","first-page":"160","article-title":"The role of P-glycoprotein in the blood-brain barrier","author":"Ramakrishnan","year":"2003","journal-title":"Einstein QJ. Biol. Med."},{"key":"10.1016\/j.jconrel.2021.05.046_bb0020","series-title":"Multidrug Resistance P-Glycoprotein (P-Gp), Glucocorticoids, and the Stress Response","author":"Bloise","year":"2019"},{"key":"10.1016\/j.jconrel.2021.05.046_bb0025","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/j.cellbi.2007.03.018","article-title":"P-glycoprotein expression in extracellular matrix formation of chondrogenic differentiation of human adult stem cells","volume":"31","author":"Gyung","year":"2007","journal-title":"Cell Biol. Int."},{"key":"10.1016\/j.jconrel.2021.05.046_bb0030","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S0169-409X(97)00504-8","article-title":"Blood-brain barrier function of P-glycoprotein","volume":"25","author":"Tsuji","year":"1997","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2021.05.046_bb0035","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.jconrel.2008.08.004","article-title":"P-Glycoprotein (Abcb1) is involved in absorptive drug transport in skin","volume":"131","author":"Ito","year":"2008","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2021.05.046_bb0040","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jconrel.2012.04.034","article-title":"Delivery of P-glycoprotein substrates using chemosensitizers and nanotechnology for selective and efficient therapeutic outcomes","volume":"161","author":"Nieto Montesinos","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2021.05.046_bb0045","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.brainresbull.2020.04.012","article-title":"Modulation of nose-to-brain delivery of a P-glycoprotein (MDR1) substrate model drug (quinidine) in rats","volume":"160","author":"Bors","year":"2020","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.jconrel.2021.05.046_bb0050","doi-asserted-by":"crossref","first-page":"5108","DOI":"10.1021\/acs.jmedchem.7b01457","article-title":"Inhibit or evade multidrug resistance P-Glycoprotein in Cancer treatment","volume":"61","author":"Waghray","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jconrel.2021.05.046_bb0055","first-page":"1","article-title":"Molecular structure of human P-glycoprotein in the ATP-bound, outward-facing conformation","volume":"7389","author":"Kim","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.jconrel.2021.05.046_bb0060","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.2174\/138161211797440122","article-title":"Blood-brain barrier P-glycoprotein function in neurodegenerative disease","volume":"17","author":"Bartels","year":"2012","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.jconrel.2021.05.046_bb0065","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/wnan.59","article-title":"Quinoline-n-butylcyanoacrylate-based nanoparticles for brain targeting for the diagnosis of Alzheimer\u2019s disease","volume":"2","author":"Kulkarni","year":"2010","journal-title":"Wiley Interdiscip. Rev. Nanomed.Nanobiotechnol."},{"key":"10.1016\/j.jconrel.2021.05.046_bb0070","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1208\/s12248-017-0081-9","article-title":"Functional expression of P-glycoprotein and organic anion transporting polypeptides at the blood-brain barrier: understanding transport mechanisms for improved CNS drug delivery?","volume":"19","author":"Abdullahi","year":"2017","journal-title":"AAPS J."},{"key":"10.1016\/j.jconrel.2021.05.046_bb0075","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.vetpar.2015.09.002","article-title":"Doxycycline as an inhibitor of p-glycoprotein in the alpaca for the purpose of maintaining avermectins in the CNS during treatment for parelaphostrongylosis","volume":"212","author":"Agbedanu","year":"2015","journal-title":"Vet. Parasitol."},{"key":"10.1016\/j.jconrel.2021.05.046_bb0080","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.nbd.2016.01.008","article-title":"CNS uptake of bortezomib is enhanced by P-glycoprotein inhibition: implications for spinal muscular atrophy","volume":"88","author":"Foran","year":"2016","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.jconrel.2021.05.046_bb0085","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1016\/0006-2952(95)02073-X","article-title":"Interaction of drugs with P-glycoprotein in brain capillaries","volume":"50","author":"Jett\u00e9","year":"1995","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.jconrel.2021.05.046_bb0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/pharmaceutics12100966","article-title":"Novel intrinsic mechanisms of active drug extrusion at the blood-brain barrier: potential targets for enhancing drug delivery to the brain?","volume":"12","author":"L\u00f6scher","year":"2020","journal-title":"Pharmaceutics."},{"key":"10.1016\/j.jconrel.2021.05.046_bb0095","first-page":"1","article-title":"Weber, Beard, Bomyea, \u57fa\u56e0\u7684\u6539\u53d8NIH public access","volume":"23","author":"Amir","year":"2008","journal-title":"Bone."},{"key":"10.1016\/j.jconrel.2021.05.046_bb0100","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1038\/jcbfm.2010.21","article-title":"Activation of PKC isoform \u0392i at the blood-brain barrier rapidly decreases P-glycoprotein activity and enhances drug delivery to the brain","volume":"30","author":"Rigor","year":"2010","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"10.1016\/j.jconrel.2021.05.046_bb0105","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1007\/s11307-012-0556-0","article-title":"P-glycoprotein function at the blood-brain barrier: effects of age and gender","volume":"14","author":"Van Assema","year":"2012","journal-title":"Mol. Imaging Biol."},{"key":"10.1016\/j.jconrel.2021.05.046_bb0110","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.jmgm.2017.12.022","article-title":"Multiscale molecular dynamics simulations of lipid interactions with P-glycoprotein in a complex membrane","volume":"80","author":"Domicevica","year":"2018","journal-title":"J. Mol. Graph. Model."},{"key":"10.1016\/j.jconrel.2021.05.046_bb0115","series-title":"P-Glycoprotein Mediated Multidrug Resistance in Normal and Neoplastic Hematopoietic Cells","author":"Herrmann","year":"1994"},{"key":"10.1016\/j.jconrel.2021.05.046_bb0120","first-page":"1","article-title":"Seminars in Cell & Developmental Biology Mesenchymal stem cell therapies in brain disease","author":"Sherman","year":"2019","journal-title":"Semin. Cell Dev. Biol."},{"key":"10.1016\/j.jconrel.2021.05.046_bb0125","author":"Pan","year":"2020","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2021.05.046_bb0130","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1517\/13543776.2011.561784","article-title":"The emerging role of P-glycoprotein inhibitors in drug delivery: a patent review","volume":"21","author":"Akhtar","year":"2011","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.jconrel.2021.05.046_bb0135","first-page":"484963","article-title":"Bypassing P-glycoprotein drug efflux mechanisms: possible applications in pharmacoresistant schizophrenia therapy","author":"Kumar Pillay","year":"2015","journal-title":"Biomed Res. Int. 2015"},{"key":"10.1016\/j.jconrel.2021.05.046_bb0140","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.semcdb.2015.01.002","article-title":"Anatomy and physiology of the blood-brain barrier","volume":"38","author":"Serlin","year":"2015","journal-title":"Semin. Cell Dev. Biol."},{"key":"10.1016\/j.jconrel.2021.05.046_bb0145","series-title":"Anatomy and Physiology of Blood-Brain Barrier","author":"Gupta","year":"2019"},{"key":"10.1016\/j.jconrel.2021.05.046_bb0150","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0169-409X(98)00085-4","article-title":"P-glycoprotein, a gatekeeper in the blood-brain barrier","volume":"36","author":"Schinkel","year":"1999","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2021.05.046_bb0155","doi-asserted-by":"crossref","first-page":"119732","DOI":"10.1016\/j.biomaterials.2019.119732","article-title":"Microphysiological systems for recapitulating physiology and function of blood-brain barrier","volume":"232","author":"Seo","year":"2020","journal-title":"Biomaterials."},{"key":"10.1016\/j.jconrel.2021.05.046_bb0160","series-title":"Blood\u2013Brain Barrier Damage and Dysfunction by Chemical Toxicity","author":"Gupta","year":"2020"},{"key":"10.1016\/j.jconrel.2021.05.046_bb0165","doi-asserted-by":"crossref","first-page":"867","DOI":"10.3109\/14756366.2016.1149476","article-title":"Advances in plant-based inhibitors of P-glycoprotein","volume":"31","author":"Yu","year":"2016","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"10.1016\/j.jconrel.2021.05.046_bb0170","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1080\/10611860400024110","article-title":"In vivo evidence for the efflux transport of pentazocine from the brain across the blood-brain barrier using the brain efflux index method","volume":"13","author":"Moriki","year":"2005","journal-title":"J. Drug Target."},{"key":"10.1016\/j.jconrel.2021.05.046_bb0175","series-title":"P-Glycoprotein Trafficking as a Therapeutic Target to Optimize CNS Drug Delivery","author":"Davis","year":"2014"},{"key":"10.1016\/j.jconrel.2021.05.046_bb0180","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/ane.12778","article-title":"Role of P-glycoprotein inhibitors in children with drug-resistant epilepsy","volume":"136","author":"Elkhayat","year":"2017","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.jconrel.2021.05.046_bb0185","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1038\/mt.2013.123","article-title":"Systemic delivery of Fusogenic membrane glycoprotein-expressing neural stem cells to selectively kill tumor cells","volume":"21","author":"Zhu","year":"2013","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2021.05.046_bb0190","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.2217\/pgs.11.55","article-title":"Relationship between P-glycoprotein and second-generation antipsychotics","volume":"12","author":"Moons","year":"2011","journal-title":"Pharmacogenomics."},{"key":"10.1016\/j.jconrel.2021.05.046_bb0195","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1007\/s00228-008-0487-5","article-title":"Effect of the novel antipsychotic drug perospirone on P-glycoprotein function and expression in Caco-2 cells","volume":"64","author":"Zhou","year":"2008","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.jconrel.2021.05.046_bb0200","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1097\/JCP.0b013e3182408fc8","article-title":"Ketoconazole-associated preferential increase in dopamine D2 receptor occupancy in striatum compared to pituitary in vivo: role for drug transporters?","volume":"32","author":"Reist","year":"2012","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.jconrel.2021.05.046_bb0205","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1021\/acs.molpharmaceut.6b01044","article-title":"Dual modulation of human P-glycoprotein and ABCG2 with prodrug dimers of the atypical antipsychotic agent paliperidone in a model of the blood-brain barrier","volume":"14","author":"Bohn","year":"2017","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2021.05.046_bb0210","series-title":"The Impact of Neurovascular, Blood-brain Barrier, and Glymphatic Dysfunction in Neurodegenerative and Metabolic Diseases","author":"Braun","year":"2020"},{"key":"10.1016\/j.jconrel.2021.05.046_bb0215","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1111\/febs.15148","article-title":"P-glycoprotein: a role in the export of amyloid-\u03b2 in Alzheimer\u2019s disease?","volume":"287","author":"Chai","year":"2020","journal-title":"FEBS J."},{"key":"10.1016\/j.jconrel.2021.05.046_bb0220","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.bbadis.2016.01.013","article-title":"Role of P-glycoprotein in mediating rivastigmine effect on amyloid-\u03b2 brain load and related pathology in Alzheimer\u2019s disease mouse model","volume":"1862","author":"Mohamed","year":"2016","journal-title":"Biochim. Biophys. Acta Mol. basis Dis."},{"key":"10.1016\/j.jconrel.2021.05.046_bb0225","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3233\/JAD-2012-120319","article-title":"Enhanced brain amyloid-\u03b2 clearance by rifampicin and caffeine as a possible protective mechanism against alzheimer\u2019s disease","volume":"31","author":"Qosa","year":"2012","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.jconrel.2021.05.046_bb0230","doi-asserted-by":"crossref","first-page":"113112","DOI":"10.1016\/j.expneurol.2019.113112","article-title":"Neural stem cell therapy for neurovascular injury in Alzheimer \u2019 s disease","volume":"324","author":"Boese","year":"2020","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.jconrel.2021.05.046_bb0235","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1002\/cpt.2035","article-title":"Abundance of P-glycoprotein and other drug transporters at the human blood-brain barrier in Alzheimer\u2019s disease: a quantitative targeted proteomic study","volume":"109","author":"Storelli","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.jconrel.2021.05.046_bb0240","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1124\/jpet.113.209791","article-title":"Absence of P-glycoprotein transport in the pharmacokinetics and toxicity of the herbicide paraquats","volume":"348","author":"Lacher","year":"2014","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.jconrel.2021.05.046_bb0245","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1124\/jpet.115.226373","article-title":"P-glycoprotein transport of neurotoxic pesticides","volume":"355","author":"Lacher","year":"2015","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.jconrel.2021.05.046_bb0250","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms21228538","article-title":"Brain endothelial p-glycoprotein level is reduced in parkinson\u2019s disease via a vitamin d receptor-dependent pathway","volume":"21","author":"Kim","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jconrel.2021.05.046_bb0255","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.bbi.2017.05.008","article-title":"Genetic deletion of P-glycoprotein alters stress responsivity and increases depression-like behavior, social withdrawal and microglial activation in the hippocampus of female mice","volume":"65","author":"Brzozowska","year":"2017","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.jconrel.2021.05.046_bb0260","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1159\/000358063","article-title":"Implication of p-glycoprotein in formation of depression-prone personality: association study between the c3435t mdr1 gene polymorphism and interpersonal sensitivity","volume":"69","author":"Enokido","year":"2014","journal-title":"Neuropsychobiology."},{"key":"10.1016\/j.jconrel.2021.05.046_bb0265","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s40262-015-0310-2","article-title":"Reliability of in vitro and in vivo methods for predicting the effect of P-glycoprotein on the delivery of antidepressants to the brain","volume":"55","author":"Zheng","year":"2016","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.jconrel.2021.05.046_bb0270","doi-asserted-by":"crossref","DOI":"10.1007\/s12015-021-10120-2","article-title":"3D printed bioconstructs: regenerative modulation for genetic expression","author":"Shende","year":"2021","journal-title":"Stem Cell Rev. Rep."},{"key":"10.1016\/j.jconrel.2021.05.046_bb0275","article-title":"Nanoconjugates-based stem cell therapy for the management of COVID-19","author":"Desai","year":"2020","journal-title":"Stem Cell Rev. Rep."},{"key":"10.1016\/j.jconrel.2021.05.046_bb0280","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1093\/neuonc\/not104","article-title":"Temozolomide downregulates P-glycoprotein expression in glioblastoma stem cells by interfering with the Wnt3a\/glycogen synthase-3 kinase\/b -catenin pathway","volume":"15","author":"Riganti","year":"2013","journal-title":"Neuro-Oncology"},{"key":"10.1016\/j.jconrel.2021.05.046_bb0285","series-title":"LABORATORY INVESTIGATION EGCG Inhibits Properties of Glioma Stem-like Cells and Synergizes with Temozolomide through Downregulation of P-glycoprotein Inhibition","author":"Zhang","year":"2014"},{"key":"10.1016\/j.jconrel.2021.05.046_bb0290","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.bcmd.2010.03.008","article-title":"Blood cells, molecules, and diseases the cancer stem cell selective inhibitor salinomycin is a p-glycoprotein inhibitor","volume":"45","author":"Riccioni","year":"2010","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.jconrel.2021.05.046_bb0295","author":"Linville","year":"2020","journal-title":"J. Microvasc. Res."},{"key":"10.1016\/j.jconrel.2021.05.046_bb0300","article-title":"Human induced pluripotent stem cells (BIONi010-C) generate tight cell monolayers with blood-brain barrier traits and functional expression of large neutral amino acid transporter 1 (SLC7A5)","volume":"1","author":"Goldeman","year":"2020","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2021.05.046_bb0305","first-page":"1","article-title":"BBA - molecular basis of disease neurological diseases at the blood-brain barrier: stemming new scienti fi c paradigms using patient-derived induced pluripotent cells","author":"Page","year":"2018","journal-title":"BBA \u2013 Mol. Basis Dis."},{"key":"10.1016\/j.jconrel.2021.05.046_bb0310","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.2217\/nnm-2017-0023","article-title":"Delivery of siRNA silencing P-gp in peptide-functionalized nanoparticles causes efflux modulation at the blood-brain barrier","volume":"12","author":"Gomes","year":"2017","journal-title":"Nanomedicine."},{"key":"10.1016\/j.jconrel.2021.05.046_bb0315","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/j.biomaterials.2011.10.025","article-title":"In vitro evidence of dysregulation of blood-brain barrier function after acute and repeated\/long-term exposure to TiO2 nanoparticles","volume":"33","author":"Brun","year":"2012","journal-title":"Biomaterials."},{"key":"10.1016\/j.jconrel.2021.05.046_bb0320","doi-asserted-by":"crossref","first-page":"837","DOI":"10.3109\/1061186X.2011.589435","article-title":"Brain-targeted delivery of paclitaxel using glutathione-coated nanoparticles for brain cancers","volume":"19","author":"Geldenhuys","year":"2011","journal-title":"J. Drug Target."},{"key":"10.1016\/j.jconrel.2021.05.046_bb0325","series-title":"Abstract 3109: Ultrasound-mediated Delivery and Distribution of Polymeric Nanoparticles in the Normal Brain Parenchyma and Melanoma Metastases","author":"Baghirov","year":"2017"},{"key":"10.1016\/j.jconrel.2021.05.046_bb0330","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0054182","article-title":"Nanoparticle mediated P-glycoprotein silencing for improved drug delivery across the blood-brain barrier: a siRNA-Chitosan approach","volume":"8","author":"Malmo","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2021.05.046_bb0335","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1021\/bc970118d","article-title":"Interactions of pluronic block copolymers with brain microvessel endothelial cells: evidence of two potential pathways for drug absorption","volume":"8","author":"Miller","year":"1997","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jconrel.2021.05.046_bb0340","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/S0022-3565(24)29254-5","article-title":"Mechanism of pluronic effect on P-glycoprotein efflux system in blood-brain barrier: contributions of energy depletion and membrane fluidization","volume":"299","author":"Batrakova","year":"2001","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.jconrel.2021.05.046_bb0345","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1007\/s11095-007-9347-8","article-title":"Natural and synthetic polymers as inhibitors of drug efflux pumps","volume":"25","author":"Werle","year":"2008","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2021.05.046_bb0350","doi-asserted-by":"crossref","first-page":"101525","DOI":"10.1016\/j.jddst.2020.101525","article-title":"Tailor-made electrically-responsive poly(acrylamide)-graft-pullulan copolymer based transdermal drug delivery systems: synthesis, characterization, in-vitro and ex-vivo evaluation: electrically-responsive graft copolymer for transdermal drug delivery","volume":"56","author":"Patil","year":"2020","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.jconrel.2021.05.046_bb0355","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.mimet.2019.03.009","article-title":"Novel biocompatible poly(acrylamide)-grafted-dextran hydrogels: synthesis, characterization and biomedical applications","volume":"159","author":"Patil","year":"2019","journal-title":"J. Microbiol. Methods"},{"key":"10.1016\/j.jconrel.2021.05.046_bb0360","doi-asserted-by":"crossref","first-page":"112099","DOI":"10.1016\/j.msec.2021.112099","article-title":"Materials Science & Engineering C Strategic conceptualization and potential of self-healing polymers in biomedical field","volume":"125","author":"Pathan","year":"2021","journal-title":"Mater. Sci. Eng. C"},{"key":"10.1016\/j.jconrel.2021.05.046_bb0365","doi-asserted-by":"crossref","first-page":"e112","DOI":"10.1016\/j.jconrel.2013.08.272","article-title":"Chitosan-modified PLGA nanoparticles as drug delivery carrier for modulating P-glycoprotein of enterocytes","volume":"172","author":"Guo","year":"2013","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2021.05.046_bb0370","series-title":"Natural Products as Alternative Choices for P-Glycoprotein (P-gp) Inhibition","first-page":"1","author":"Inhibition","year":"2021"},{"key":"10.1016\/j.jconrel.2021.05.046_bb0375","series-title":"Efficacy of Astragaloside IV in Experimental Autoimmune Encephalomyelitis Mice","first-page":"3","author":"Zhang","year":"2019"},{"key":"10.1016\/j.jconrel.2021.05.046_bb0380","series-title":"Natural Flavonoids Silymarin and Quercetin Improve the Brain Distribution of Co - administered P - gp Substrate Drugs","first-page":"1","author":"Reddy","year":"2016"},{"key":"10.1016\/j.jconrel.2021.05.046_bb0385","first-page":"1","article-title":"Quercetin acts as a P-gp modulator via impeding signal transduction from nucleotide-binding domain to transmembrane domain","author":"Singh","year":"2020","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.jconrel.2021.05.046_bb0390","series-title":"Modulation of Pgp Function by Boswellic Acids","author":"Weber","year":"2021"},{"key":"10.1016\/j.jconrel.2021.05.046_bb0395","series-title":"Herbal Modulation of P-Glycoprotein, 36","first-page":"57","author":"Zhou","year":"2004"},{"key":"10.1016\/j.jconrel.2021.05.046_bb0400","series-title":"US CR, Life Sci","author":"Joshi","year":"2018"},{"key":"10.1016\/j.jconrel.2021.05.046_bb0405","author":"Bharate","year":"2015","journal-title":"Biomol. Chem."},{"key":"10.1016\/j.jconrel.2021.05.046_bb0410","first-page":"1030","article-title":"Phytomedicine in vitro to in vivo evidence of the inhibitor characteristics of Schisandra lignans toward P-glycoprotein","volume":"20","author":"Liang","year":"2013","journal-title":"Eur. J. Integr. Med."},{"key":"10.1016\/j.jconrel.2021.05.046_bb0415","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1124\/dmd.114.058685","article-title":"Modulation of P-glycoprotein at the human blood-brain barrier by quinidine or rifampin treatment: a positron emission tomography imaging study","volume":"43","author":"Liu","year":"2015","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.jconrel.2021.05.046_bb0420","doi-asserted-by":"crossref","DOI":"10.1007\/s11095-018-2377-6","article-title":"Ionophore and biometal modulation of P-glycoprotein expression and function in human brain microvascular endothelial cells","volume":"35","author":"McInerney","year":"2018","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2021.05.046_bb0425","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.bcp.2003.08.027","article-title":"Variable modulation of opioid brain uptake by P-glycoprotein in mice","volume":"67","author":"Dagenais","year":"2004","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.jconrel.2021.05.046_bb0430","first-page":"250","article-title":"Multiscale molecular dynamics simulations of lipid interactions with P-glycoprotein in a complex membrane","volume":"77","author":"Domicevica","year":"2017","journal-title":"J. Mol. Graph. Model."},{"key":"10.1016\/j.jconrel.2021.05.046_bb0435","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.taap.2016.03.008","article-title":"In vitro and in vivo evaluations of the P-glycoprotein-mediated efflux of dibenzoylhydrazines","volume":"298","author":"Miyata","year":"2016","journal-title":"Toxicol. Appl. Pharmacol."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365921002807?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365921002807?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T16:03:09Z","timestamp":1759161789000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365921002807"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":87,"alternative-id":["S0168365921002807"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2021.05.046","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tailoring of P-glycoprotein for effective transportation of actives across blood-brain-barrier","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2021.05.046","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}